Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

What Does the Future Hold for Nextcure?

TheMotleyFool

0 0

Quietly on Jan. 13, Nextcure (NASDAQ: NXTC) filed a terse 8-K with the SEC stating that Eli Lilly (NYSE: LLY) was terminating a research and development pact forged in November 2018. Nextcure's stock righted itself after a brief sell-off the morning after the filing.

Image source: Getty Images.

Here's why investors shouldn't worry. While Eli Lilly provided a degree of validation to Nextcure's scientific approach, the programs focused on immuno-oncology were still in early stages with few public details. Some investors may interpret the termination as a sign that the technology does not work. I suggest those investors look closer at changes at Eli Lilly.

Source Fool.com

Like: 0

NXTC

Share